Clinical Trial Update: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

View source ↗

Summary

This entry describes an expanded-access, multi-center, single-arm, open-label study of plerixafor for patients with non-Hodgkin's lymphoma, Hodgkin's disease, o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Disease
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Mozobil (plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease | Status: NO_LONGER_AVAILABLE